Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Megan Ann Baumgart"'
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Autor:
Rachel E. Sanborn, John E. Leonard, Crystal Mallow, Megan Ann Baumgart, Andreas Schröder, Nashat Y. Gabrail, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer, Nagashree Seetharamu, JT Beck, Michael Shafique, Elizabeth E. Evans, Desa Rae Pastore, Ramaswamy Govindan, Ernest S. Smith, Kevin M. Chin, Yanyan Lou, Terrence L. Fisher, Vikas Mishra, Alexander I. Spira
Publikováno v:
Clinical Cancer Research. 27:3630-3640
Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea0008ccd13e735695a07df1366c39e
https://doi.org/10.1158/1078-0432.ccr-20-4792
https://doi.org/10.1158/1078-0432.ccr-20-4792
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 5:401-408
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of malignancies which make up approximately 5% of all cancers worldwide. Molecular profiling of HNSCC tumors has identified ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::518079d4fea813ea09969e038f6682de
https://doi.org/10.1080/23808993.2020.1799710
https://doi.org/10.1080/23808993.2020.1799710
Publikováno v:
Journal of Clinical Oncology. 39:11538-11538
11538 Background: Sarcoma subtypes are often defined by recurrent molecular alterations. The purpose of this study is to review the utility of next generation sequencing (NGS) in sarcoma patients and report clinical outcomes to matched therapies. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d8ab4ad5651c4fddfa234a605266d07
https://doi.org/10.1200/jco.2021.39.15_suppl.11538
https://doi.org/10.1200/jco.2021.39.15_suppl.11538
Autor:
Karen Kelly, Gordan Srkalovic, Jonathan W. Riess, Roy S. Herbst, Katherine Minichiello, David R. Gandara, Raymond U. Osarogiagbon, Larry R. Corum, Lu Qian, Megan Ann Baumgart, Liza C. Villaruz, Mary W. Redman, Bryan A. Faller, Aruna C. Gowda, Paul Wheatley-Price
Publikováno v:
Journal of Clinical Oncology. 39:9024-9024
9024 Background: While prior studies have shown robust efficacy leading to FDA approval of PARP inhibitors (PARPi) in BRCA-associated cancers, data in NSCLC are much less clear. S1900A, a LUNG-MAP substudy, evaluated the PARPi rucaparib in advanced s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::365b563a5802bd891793ccfb998afa25
https://doi.org/10.1200/jco.2021.39.15_suppl.9024
https://doi.org/10.1200/jco.2021.39.15_suppl.9024
Autor:
Megan Ann Baumgart, Kishan J. Pandya
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 1:25-36
Over the last fifteen years, significant advances have been made in understanding the mechanisms and pathways that drive tumor growth in patients with non-small cell lung cancer (NSCLC). Molecular testing has become routine, and results directly impa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc82aa7feb81e58e019e016a1ef3c2a2
https://doi.org/10.1080/23808993.2016.1136558
https://doi.org/10.1080/23808993.2016.1136558
Autor:
Kevin M. Chin, Jonathan W. Goldman, Alexander I. Spira, Nashat Y. Gabrail, Thaddeaus Beck, Rachel E. Sanborn, John E. Leonard, Terrence L. Fisher, Ernest S. Smith, Yanyan Lou, Megan Ann Baumgart, Maurice Zauderer, Ramaswamy Govindan, Elizabeth E. Evans, Desa Rae Pastore, Nagashree Seetharamu, Michael Shafique, Crystal Mallow, Aaron S. Mansfield, Andreas Schroeder
Publikováno v:
Cancer Research. 80:CT191-CT191
Despite progress of immune checkpoint therapies, many cases of non-small cell lung cancer (NSCLC) are refractory or acquire resistance to current therapies. Antibody blockade of semaphorin 4D (SEMA4D, CD100) can overcome resistance mechanisms of immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::194c0ddec14698ceb170dde12195cbc4
https://doi.org/10.1158/1538-7445.am2020-ct191
https://doi.org/10.1158/1538-7445.am2020-ct191
Autor:
Desa Rae Pastore, Kevin M. Chin, Nashat Y. Gabrail, JT Beck, Aaron S. Mansfield, Andreas Schröder, Alexander I. Spira, Yanyan Lou, Michael Shafique, Crystal Mallow, Megan Ann Baumgart, Terrence L. Fisher, Ernest S. Smith, Rachel E. Sanborn, Nagashree Seetharamu, Maurice Zauderer, Elizabeth E. Evans, Ramaswamy Govindan, John E. Leonard, Jonathan W. Goldman
Publikováno v:
Journal of Clinical Oncology. 38:3011-3011
3011 Background: Antibody blockade of semaphorin 4D (SEMA4D, CD100) promotes tumoral dendritic cell and CD8+ T cell infiltration and reduces function and recruitment of immunosuppressive myeloid cells. Importantly, these mechanisms to overcome immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6c581a538b56a973ba3ef17fd787638
https://doi.org/10.1200/jco.2020.38.15_suppl.3011
https://doi.org/10.1200/jco.2020.38.15_suppl.3011
Autor:
Andreas Schröder, Ramaswamy Govindan, Elizabeth E. Evans, Jonathan W. Goldman, John E. Leonard, Nagashree Seetharamu, Kevin M. Chin, Megan Ann Baumgart, Desa Rae Pastore, Yan Yan Lou, Rachel E. Sanborn, Aaron S. Mansfield, Nashat Y. Gabrail, Terrence L. Fisher, J. Thaddeus Beck, Ernest S. Smith, Maurice Zauderer, Alexander I. Spira, Crystal Mallow, Michael Shafique
Publikováno v:
Journal of Clinical Oncology. 38:75-75
75 Background: Despite progress of immune checkpoint therapies, many cases of non-small cell lung cancer (NSCLC) are refractory or acquire resistance to current therapies. Antibody blockade of semaphorin 4D (SEMA4D, CD100) can overcome resistance mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::493506523e5b148f1bac6b326ceaf0f8
https://doi.org/10.1200/jco.2020.38.5_suppl.75
https://doi.org/10.1200/jco.2020.38.5_suppl.75
Autor:
Masoud Azodi, Megan Ann Baumgart, Indukala Doddamane, Catherine Sullivan, David P. Tuck, Nianhang Chen, Christos Hatzis, Maysa M. Abu-Khalaf, Peter E. Schwartz, Michael P. DiGiovanna, Lyndsay Harris, Hari Anant Deshpande, Daniel Zelterman, Kimberly Lezon-Geyda, Shihe Hou, Scott N. Gettinger
Publikováno v:
Cancer. 121:1817-1826
BACKGROUND The optimal weekly oral dose of sirolimus and intravenous nanoparticle albumin–bound paclitaxel (nab-paclitaxel) were evaluated. METHODS A phase 1b study was performed to evaluate escalating doses of oral sirolimus (5-60 mg) on days 2, 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9d54d90d2dae388773988384e40fd7d
https://doi.org/10.1002/cncr.29254
https://doi.org/10.1002/cncr.29254
Autor:
Karim Welaya, Manidhar Reddy Lekkala, Dwight Hettler, Julie Ann Berkhof, Bahar Moftakhar, Karen J. Abbas, Jason H. Mendler, Megan Ann Baumgart, Dilip Sankar Babu, Titas Banerjee, Carissa Treptow, Nabeel Badri
Publikováno v:
Journal of Clinical Oncology. 37:12-12
12 Background: Inpatient mortality, defined as death within 30 days of an acute hospital admission, is often used as a quality benchmark for healthcare institutions and is an important metric for evaluating quality of care of patients with advanced m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97b9b4544a38cb7c9650b0a9e49195d2
https://doi.org/10.1200/jco.2019.37.27_suppl.12
https://doi.org/10.1200/jco.2019.37.27_suppl.12